Arovella Therapeutics (ALA) Corporate presentation summary

Investment highlights and leadership

• U.S. FDA IND accepted for ALA-101, with phase 1 trials for CD19-positive blood cancers expected in FY 2026.

• Developing off-the-shelf iNKT cell therapies for blood and solid tumour cancers.

• Proprietary clinic-ready manufacturing process for CAR-iNKT cells established.

• Strategic acquisitions and a leadership team with proven cell therapy experience.

• Strong scientific and clinical advisory boards with global experts.

Financial overview

• Market capitalisation of $104.58 million as of January 2025, with $19.4 million cash at 31 Dec 2025.

• Major shareholders include Biotech Capital Management (5.78%) and Richard John Mann (5.76%).

• Share price ranged from $0.068 to $0.195 over the past year.

Cell therapy market and technology

• CAR-T therapies have revolutionised blood cancer treatment, with a market expected to reach $15.2 billion by 2035.

• Current CAR-T therapies are patient-specific, costly, and slow to manufacture.

• iNKT cells offer off-the-shelf potential, strong safety, and do not cause GVHD.

• iNKT cells bridge innate and adaptive immunity, naturally target cancer, and modulate the tumour microenvironment.